Business
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING®, to treat chronic HBV infection SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmace
About this update from Xiamen Amoytop Biotech Co., Ltd. Class A
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vlfQz4YXE1OChvpvo4LFnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Aligos to receive an upfront payment of $25M USD","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Amoytop to fund its development program in Greater China","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Amoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING®, to treat chronic HBV infection","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":355,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”) in Greater China, which includes Mainland China, Taiwan, Hong Kong, and Macau for chronic hepatitis B virus (HBV) infection.","length":556,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Aligos will receive an upfront milestone of $25M USD and is eligible to receive up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop’s licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and all other markets. In addition, Aligos will retain the right to conduct clinical trials in Greater China. With more than 90 mi...